Cancer EV Isolation via CA19-9 Antibody Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and concentrating extracellular vesicles (EVs) from blood are not sensitive or accurate enough, particularly for specific subsets of EVs derived from cancer cells, which hinders effective cancer diagnosis and treatment.
Innovation Solution
A method involving the use of a substance with affinity for the carbohydrate antigen CA19-9, such as an anti-CA19-9 antibody, to isolate and concentrate EVs from cancer cells by immunoprecipitation, allowing for precise identification and analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If collective analysis of extracellular vesicles in blood is performed, then analysis coverage is improved, but sensitivity and accuracy deteriorate due to miscellaneous population
Solution Approach 1:
The patent segments the miscellaneous extracellular vesicle population by using anti-CA19-9 antibodies to specifically bind and isolate CA19-9 positive EVs from cancer cells, separating them from other EVs in the blood sample. This segmentation enables both comprehensive cancer-related analysis and high sensitivity/detection accuracy for cancer-specific markers.
2Measurement precision
If specific isolation of cancer-derived extracellular vesicles is achieved, then diagnostic accuracy is improved, but isolation complexity increases
Solution Approach 1:
The patent uses anti-CA19-9 antibodies as intermediary molecules that specifically bind to CA19-9 antigens on the surface of cancer-derived EVs. These antibodies act as mediators between the complex isolation process and the target EVs, enabling specific isolation through immunomagnetic separation or immunoprecipitation methods, thereby achieving high diagnostic accuracy without excessive complexity.
3Ease of operation
If noninvasive cancer diagnosis is implemented through blood EV analysis, then patient comfort is improved, but detection sensitivity deteriorates without specific isolation
Solution Approach 1:
The patent extracts and isolates the specific diagnostic information contained in CA19-9 positive EVs from the complex blood sample matrix. By taking out only the cancer-relevant EVs through antibody-specific binding and isolation, the method maintains the noninvasive advantage of blood sampling while achieving high detection sensitivity for cancer markers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables highly accurate and noninvasive cancer diagnosis by specifically isolating and concentrating cancer-derived EVs, facilitating further analysis and drug selection based on patient genotype.
Implementation Method 1
bringing a substance having an affinity for a carbohydrate antigen CA19-9 into contact with an extracellular vesicle group which has been isolated from blood derived from a patient
Data Source
AI summary
A method for isolating and concentrating an extracellular vesicle group derived from a cancer cell involves contacting a substance which has affinity towards a carbohydrate antigen CA19-9 with an extracellular vesicle group which has been isolated from blood derived from a patient, and isolating and concentrating an extracellular vesicle group.